Infant-type hemispheric gliomas, also known as infant high-grade gliomas, are high-grade brain tumors occurring in children.
On this page:
Terminology
Infant-type hemispheric gliomas belong to the family of "pediatric high-grade diffuse gliomas" of the 2021 WHO Classification of Tumors of the Central Nervous System 1. They have been recently recognized as a novel tumor type distinct from other pediatric high-grade gliomas, harboring molecular mutations involving the receptor tyrosine kinases NTRK, ROS1, ALK, and MET.
Epidemiology
Infant-type hemispheric gliomas typically arise in the first year of life (range: 0–12 months) 2.
Pathology
Subtypes
- infant-type hemispheric glioma, NTRK-altered
- infant-type hemispheric glioma, ROS1-altered
- infant-type hemispheric glioma, ALK-altered
- infant-type hemispheric glioma, MET-altered
Location
They are usually supratentorial 2,3.
Microscopic appearance
Infant-type hemispheric gliomas show astrocytic cells arranged in fascicles or sheets with mild to moderate pleomorphism. Moreover, like the other high-grade gliomas, they often display palisading necrosis, mitotic activity, and endothelial proliferation 2,3.
Immunophenotype and molecular alterations
- GFAP: positive
- ALK: sometimes positive in the infant-type hemispheric glioma ALK-altered
- diagnosis of these tumors generally requires detection of the fusion genes of tyrosine kinase NTRK1, NTRK2, NTRK3, ROS1, ALK, MET or, alternatively, a characteristic methylation profile 1-3
Radiographic features
An infant-type hemispheric glioma usually appears as a huge supratentorial mass with vasogenic edema, exerting a significant mass effect on the surrounding intracranial structures. Cases of leptomeningeal dissemination have been reported 4.
MRI
- show a heterogeneous signal on T1W and T2W sequences, often with necrosis and hemorrhage
- enhancement is present and is heterogeneous 2,3
Treatment and prognosis
More studies are needed to evaluate the survival rate and impact of targeted therapies. Infant-type hemispheric glioma ALK-altered subtype seems to have a better 5-year survival rate than the ROS1- and NTRK-altered subtypes 2.